Adam Crystal Sells 27,000 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock

Posted by Brenda Bartman on Jul 4th, 2026

Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total transaction of $798,930.00. Following the sale, the insider owned 115,743 shares in the company, valued at $3,424,835.37. This represents a 18.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Adam Crystal also recently made the following trade(s):

On Monday, June 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $22.87, for a total transaction of $617,490.00.
On Friday, May 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $21.23, for a total transaction of $573,210.00.
On Wednesday, April 15th, Adam Crystal sold 38,460 shares of Tango Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $961,500.00.

Tango Therapeutics Stock Performance

Shares of Tango Therapeutics stock opened at $29.46 on Friday. The firm has a market cap of $4.26 billion, a P/E ratio of -35.49 and a beta of 1.12. The firm’s 50-day simple moving average is $25.55 and its 200-day simple moving average is $18.49. Tango Therapeutics, Inc. has a twelve month low of $5.34 and a twelve month high of $34.39.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.32). On average, equities analysts forecast that Tango Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Institutional Trading of Tango Therapeutics

Several hedge funds have recently modified their holdings of TNGX. Farallon Capital Management LLC raised its stake in shares of Tango Therapeutics by 21.4% in the fourth quarter. Farallon Capital Management LLC now owns 13,061,411 shares of the company’s stock valued at $115,724,000 after acquiring an additional 2,304,411 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its position in Tango Therapeutics by 322.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company’s stock worth $93,986,000 after acquiring an additional 8,096,924 shares during the last quarter. Siren L.L.C. grew its position in Tango Therapeutics by 38.8% during the 4th quarter. Siren L.L.C. now owns 8,165,374 shares of the company’s stock worth $72,345,000 after acquiring an additional 2,282,186 shares during the last quarter. Vanguard Group Inc. increased its holdings in Tango Therapeutics by 33.6% during the 4th quarter. Vanguard Group Inc. now owns 6,750,977 shares of the company’s stock valued at $59,814,000 after purchasing an additional 1,698,974 shares in the last quarter. Finally, State Street Corp increased its holdings in Tango Therapeutics by 84.8% during the 4th quarter. State Street Corp now owns 6,218,567 shares of the company’s stock valued at $55,097,000 after purchasing an additional 2,853,362 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Mizuho set a $36.00 target price on Tango Therapeutics in a report on Monday, June 8th. Citigroup reaffirmed a “buy” rating on shares of Tango Therapeutics in a research note on Monday, April 27th. Raymond James Financial cut Tango Therapeutics to a “hold” rating in a research report on Thursday, June 25th. HC Wainwright increased their price objective on Tango Therapeutics from $27.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Finally, Canaccord Genuity Group lifted their price objective on Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, June 29th. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Tango Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $41.50.

Read Our Latest Analysis on Tango Therapeutics

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.